Vale Mariana L, Benevides Verônica M, Sachs Daniela, Brito Gerly A C, da Rocha Francisco A C, Poole Stephen, Ferreira Sérgio H, Cunha Fernando Q, Ribeiro Ronaldo A
Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel, Nunes de Melo, 1127, CEP 60430-270, Fortaleza, CE, Brazil.
Br J Pharmacol. 2004 Dec;143(7):833-44. doi: 10.1038/sj.bjp.0705999. Epub 2004 Nov 1.
The antihyperalgesic effect of pentoxifylline was investigated in three experimental pain models. Pentoxifylline (0.5-1.6 mg kg(-1)) given 30 min before the stimulus significantly inhibited the writhing response induced by the intraperitoneal (i.p.) administration of either acetic acid (-90%) or zymosan (-83%), but not that of iloprost, in mice, as well as the zymosan-induced articular hyperalgesia in the zymosan arthritis in rats (-50%). Pentoxifylline also inhibited the mechanical hypernociception in rats induced by the intraplantar injection of either carrageenin (-81%), bradykinin (-56%) or tumor necrosis factor alpha (TNF-alpha; -46%), but not that induced by interleukin-1beta (IL-1beta) or prostaglandin E(2) (PGE(2)). Pentoxifylline did not inhibit the nociceptive response in the hot plate test in mice. Further, the antinociceptive effect of pentoxifylline in the writhing test in mice and the zymosan-induced articular hyperalgesia were not reversed by the coadministration of the opioid receptor antagonist naloxone. Thus, pentoxifylline antinociceptive effect is probably not mediated at a central level. Pentoxifylline significantly reduced TNF-alpha (-43%) and IL-1beta (-42%) concentrations in the joint exudates of rats stimulated by intra-articular injection of zymosan and the production of both cytokines (-66 and -86%, respectively) by mouse peritoneal macrophages stimulated in vivo with zymosan as well as the expression of TNF-alpha at the tissue level in carrageenin-injected rat paws. In conclusion, the antinociceptive activity of pentoxifylline is associated with the inhibition of the release of both TNF-alpha and IL-1beta.
在三种实验性疼痛模型中研究了己酮可可碱的抗痛觉过敏作用。在刺激前30分钟给予己酮可可碱(0.5 - 1.6毫克/千克)可显著抑制小鼠腹腔注射醋酸(-90%)或酵母聚糖(-83%)诱导的扭体反应,但对伊洛前列素诱导的扭体反应无效,同时也可抑制大鼠酵母聚糖性关节炎中酵母聚糖诱导的关节痛觉过敏(-50%)。己酮可可碱还可抑制大鼠足底注射角叉菜胶(-81%)、缓激肽(-56%)或肿瘤坏死因子α(TNF-α;-46%)诱导的机械性痛觉过敏,但对白细胞介素-1β(IL-1β)或前列腺素E2(PGE2)诱导的痛觉过敏无效。己酮可可碱在小鼠热板试验中不抑制伤害性反应。此外,在小鼠扭体试验和酵母聚糖诱导的关节痛觉过敏中,己酮可可碱的镇痛作用不会因同时给予阿片受体拮抗剂纳洛酮而逆转。因此,己酮可可碱的镇痛作用可能不是在中枢水平介导的。己酮可可碱可显著降低关节腔内注射酵母聚糖刺激的大鼠关节渗出液中TNF-α(-43%)和IL-1β(-42%)的浓度,以及体内用酵母聚糖刺激的小鼠腹腔巨噬细胞中两种细胞因子的产生(分别为-66%和-86%),同时还可降低角叉菜胶注射的大鼠爪组织水平上TNF-α的表达。总之,己酮可可碱的镇痛活性与抑制TNF-α和IL-1β的释放有关。